| Value | ₹2.63 Cr |
|---|
BSE filing, NSE: PHARMAID. Summary written from the filing by ALFA Finder's alert engine.
Pharmaids Pharmaceuticals Ltd: key numbers
- Share price
- ₹28.42
- Market cap
- ₹100.2 Cr
- Revenue (annual)
- ₹27.88 Cr
- Net profit (annual)
- ₹-11.72 Cr
- P/E (TTM)
- -22.0×Sector 48.7×
- Promoter holding
- 32.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Pharmaids Pharmaceuticals Ltd
All →Pharmaids Pharmaceuticals Other Announcement
Pharmaids Pharmaceuticals Limited filed its quarterly Regulation 74(5) compliance certificate from its Registrar and Share Transfer Agent confirming the dematerialization of shares.
Pharmaids Pharmaceuticals Annual General Meeting
Pharmaids Pharmaceuticals held its 37th AGM via video conference on 11 Sept 2026. Four resolutions including adoption of FY26 financials and related-party-transaction approvals were tabled.
Pharmaids Pharmaceuticals Promoter Buying (Off-Market)
KMP Prasanna Subramanya Bhat acquired 17,291 shares of Pharmaids Pharmaceuticals Ltd via a gift from an immediate relative. This off-market transfer is an insider disclosure.
- Promoter stake change
- +0.04%
Pharmaids Pharmaceuticals Annual General Meeting
Pharmaids Pharmaceuticals Limited has issued the notice for its 37th Annual General Meeting, scheduled for September 11, 2026, along with the Annual Report for 2025-26.
Pharmaids Pharmaceuticals Q1 FY27 Results: Net Profit ₹1.9 Cr, Down 64.2% YoY
Pharmaids Pharmaceuticals Ltd reported revenue from operations of ₹4.1 Cr (-38.8% YoY) and net profit of ₹1.9 Cr (-64.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.9 Cr · -64.2% YoY
Pharmaids Pharmaceuticals Board Meeting Date
Pharmaids Pharmaceuticals scheduled a board meeting for August 12, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.
Other legal & regulatory announcements
All →5Paisa Capital Legal & Regulatory
5paisa Capital Ltd received a favourable income tax order for AY 2023-24, granting relief of ₹40.03 crore against a total disputed amount of ₹42.90 crore.
- Value
- ₹40.03 Cr
5Paisa Capital Legal & Regulatory
5paisa Capital's appeal against an Income Tax order for A.Y. 2023-24 was partly allowed, granting the company relief of ₹40.03 Crore.
- Value
- ₹42.90 Cr
Max Healthcare Institute Legal & Regulatory
Max Healthcare informed the Exchange that the NCLT hearing regarding petitions against its subsidiary, Kalinga Hospital Ltd., was adjourned to October 30, 2026.
Bank of Baroda Legal & Regulatory
Bank of Baroda clarified media-reported interim applications filed by Dr. BR Shetty in the Bombay High Court. The bank says it has not been served and calls the allegations untested.
Canara Bank Legal & Regulatory
Canara Bank disclosed an RBI penalty of Rs. 7,30,000 over ATM cashout at 73 ATMs in Karnataka and Tamil Nadu. The penalty is the only quantified impact.
- Value
- ₹0.07 Cr
Rentomojo Legal & Regulatory
Rentomojo disclosed that the NCLT Bengaluru proceedings filed by Mr. Ajay Nain (CP No. 38/2026) were adjourned to December 1, 2026. No monetary amount is involved.